Adma Biologics (ADMA) stock in plain English
Every company we rate gets Strong Buy, Buy, Buy with Caution, Hold or Sell. Members see the rating for this company and the five scores behind it.
Change shown by the quote provider. Data may be delayed.
What does Adma Biologics (ADMA) do?
Adma Biologics Inc (ADMA) is a U.S.-listed company in Healthcare (Biotechnology). What it does: Manufactures specialized plasma-derived biologics to treat patients with immunodeficiencies and infectious disease risks. It collects human plasma and fractionates specialty hyperimmune treatments through its own vertically integrated. It is worth $2.96B on the market and sold $519.22M over the last year.
- Market cap
- $2.96B
- P/E ratio
- 17.2×
- Annual sales
- $519.22M
- Sector
- Healthcare
- Industry
- Biotechnology
- Brief updated
- Nov 12, 2026
Brands and businesses behind ADMA
- ASCENIV: It is a patented intravenous hyperimmune therapy that generates revenue from sales to treat immune-deficient patients.
- BIVIGAM: It is an intravenous immune globulin therapy sold to specialty distributors for patients with primary humoral immunodeficiency.
- Nabi-HB: It is a specialized hepatitis B immune globulin treatment sold to prevent infection following acute exposure.
ADMA’s flags, in plain English
Each flag is a number from Adma Biologics’ reports to the SEC or from market data, with the reason it matters. This brief was updated on Nov 12, 2026.
Stupid Cash
Can pay this year's bills 6 times over. Cash in the bank covers a long stretch of running costs. The company can fund itself without borrowing or selling new shares.
Fat Margins
Profit margin of 35.1%. The company keeps a healthy share of each sale as profit, which gives it room when costs jump.
Earns Its Keep
Earns 42% a year on shareholders' money. The company earns a healthy return on the money its shareholders have put in.
Worth a Look
Hospital distributor payment delays slow down cash collection on delivered immune globulin therapies. Something here could change the picture, so it is worth reading next to the good news.
2 more green flags open with the free trial. Try it free for 7 days.
Questions about ADMA
How big is Adma Biologics?
Adma Biologics’ market cap is $2.96B: what all of its shares are worth together at today’s price. Its annual sales (revenue) are $519.22M: what customers paid the company over the last year, before any costs.
What is ADMA’s P/E ratio?
ADMA’s P/E ratio is 17.2×. Investors pay about 17.2 dollars for each dollar of the company’s yearly profit. A low number can mean a bargain or a problem, so read it next to the flags.
What could go wrong with ADMA?
The first risk note on the card is Worth a Look, explained above. A flag reads what the company reported. It does not predict the price.
Where do these numbers come from?
From Adma Biologics’ own reports to the SEC (annual and quarterly) and from market data. Every company runs through the same scoring formula, and a reviewer spot-checks cards against the source data. ADMA’s filings on SEC.gov. The Margin Monkey is research, not advice.
